glp 1 drugs oral Comparing Ozempic, Wegovy and Other GLP-1 Oral GLP-1 Therapy for Obesity

Ahrn, B

Hypoxia-Inducible factor is critical for pathogenesis and regulation of immune cell functions in rheumatoid arthritis

reported greater weight loss in obese mice with the GLP-1/GIP/glucagon receptor triagonist compared to GLP-1 receptor agonists, GIP/GLP-1 receptor co-agonists and GLP-1/glucagon receptor agonists including semaglutide and tirzepatide [60]

doi: 10.1038/s41366-025-01859-6

They are released throughout the day, increasing at mealtimes, and have several functions: Stimulate the production and secretion of insulin in response to eating (glucose-dependent insulin secretion) GLP-1 enhances the sensitivity of alpha cells to glucose, resulting in more glucose-appropriate glucagon secretion Slow digestion and decrease appetite Thus, DPP-4 inhibitors indirectly enhance insulin release, suppress glucagon secretion, and improve glycaemic control

Each starts at a low dose that can be increased every four weeks as tolerated and needed